UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 812

Sortiert nach

Systematic review and network meta‐analysis: first‐ and second‐line biologic therapies for moderate‐severe Crohn's disease

Alimentary pharmacology & therapeutics, 2018-08, Vol.48 (4), p.394-409

2018

Link zum Volltext

Verfügbarkeit prüfen

Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing: 2013 Update

Clinical pharmacology and therapeutics, 2013-04, Vol.93 (4), p.324-325

2013

Link zum Volltext

Verfügbarkeit prüfen

Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing

Clinical pharmacology and therapeutics, 2011-03, Vol.89 (3), p.387-391

2011

Link zum Volltext

Verfügbarkeit prüfen

Long‐term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy

Alimentary pharmacology & therapeutics, 2018-07, Vol.48 (1), p.65-77

2018

Link zum Volltext

Verfügbarkeit prüfen

Adalimumab for the treatment of fistulas in patients with Crohn’s disease

Gut, 2009-07, Vol.58 (7), p.940-948

2009

Link zum Volltext

Verfügbarkeit prüfen

A retrospective analysis: the development of patient reported outcome measures for the assessment of Crohn's disease activity

Alimentary pharmacology & therapeutics, 2015-01, Vol.41 (1), p.77-86

2015

Link zum Volltext

Verfügbarkeit prüfen

Development of interim patient‐reported outcome measures for the assessment of ulcerative colitis disease activity in clinical trials

Alimentary pharmacology & therapeutics, 2015-11, Vol.42 (10), p.1200-1210

2015

Link zum Volltext

Verfügbarkeit prüfen

The epidemiology and natural history of Crohn’s disease in population‐based patient cohorts from North America: a systematic review

Alimentary pharmacology & therapeutics, 2002-01, Vol.16 (1), p.51-60

2002

Link zum Volltext

Verfügbarkeit prüfen

PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis

Gut, 2005-01, Vol.54 (1), p.91-96

2005

Link zum Volltext

Verfügbarkeit prüfen

Review article: dose optimisation of infliximab for acute severe ulcerative colitis

Alimentary pharmacology & therapeutics, 2017-03, Vol.45 (5), p.617-630

2017

Link zum Volltext

Verfügbarkeit prüfen

Randomised clinical trial: the safety and tolerability of Trichuris suis ova in patients with Crohn's disease

Alimentary pharmacology & therapeutics, 2013-08, Vol.38 (3), p.255-263

2013

Link zum Volltext

Verfügbarkeit prüfen

Long‐term safety and efficacy of certolizumab pegol in the treatment of Crohn's disease: 7‐year results from the PRECiSE 3 study

Alimentary pharmacology & therapeutics, 2014-10, Vol.40 (8), p.903-916

2014

Link zum Volltext

Verfügbarkeit prüfen

One‐year maintenance outcomes among patients with moderately‐to‐severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2

Alimentary pharmacology & therapeutics, 2013-01, Vol.37 (2), p.204-213

2013

Link zum Volltext

Verfügbarkeit prüfen

Randomised clinical trial: certolizumab pegol for fistulas in Crohn’s disease – subgroup results from a placebo‐controlled study

Alimentary pharmacology & therapeutics, 2011-01, Vol.33 (2), p.185-193

2011

Link zum Volltext

Verfügbarkeit prüfen

A prospective cohort study to determine the relationship between serum infliximab concentration and efficacy in patients with luminal Crohn's disease

Alimentary pharmacology & therapeutics, 2014-05, Vol.39 (10), p.1126-1135

2014

Link zum Volltext

Verfügbarkeit prüfen

Quantitative measurement and visual assessment of ileal Crohn’s disease activity by computed tomography enterography: correlation with endoscopic severity and C reactive protein

Gut, 2006-11, Vol.55 (11), p.1561-1567

2006

Link zum Volltext

Verfügbarkeit prüfen

Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD‐subgroup analyses across four randomized trials

Alimentary pharmacology & therapeutics, 2009-08, Vol.30 (3), p.210-226

2009

Link zum Volltext

Verfügbarkeit prüfen

Review article: biological activity markers in inflammatory bowel disease

Alimentary pharmacology & therapeutics, 2007-02, Vol.25 (3), p.247-255

2007

Link zum Volltext

Verfügbarkeit prüfen

Review article: moving towards common therapeutic goals in Crohn's disease and rheumatoid arthritis

Alimentary Pharmacology & Therapeutics (Suppl), 2017-04, Vol.45 (8), p.1058-1072

2017

Link zum Volltext

Verfügbarkeit prüfen

Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn's disease

Alimentary pharmacology & therapeutics, 2005-03, Vol.21 (6), p.733-738

2005

Link zum Volltext

Verfügbarkeit prüfen

Systematic review: the management of pouchitis

Alimentary pharmacology & therapeutics, 2006-04, Vol.23 (8), p.1087-1096

2006

Link zum Volltext

Verfügbarkeit prüfen

CDP571, a humanised monoclonal antibody to tumour necrosis factor α, for moderate to severe Crohn’s disease: a randomised, double blind, placebo controlled trial

Gut, 2004-10, Vol.53 (10), p.1485-1493

2004

Link zum Volltext

Verfügbarkeit prüfen

Review article: a clinician's guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease

Alimentary pharmacology & therapeutics, 2013-09, Vol.38 (5), p.447-459

2013

Link zum Volltext

Verfügbarkeit prüfen

Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn’s disease

Alimentary pharmacology & therapeutics, 2010-06, Vol.31 (12), p.1296-1309

2010

Link zum Volltext

Verfügbarkeit prüfen

Review article: treatment algorithms to maximize remission and minimize corticosteroid dependence in patients with inflammatory bowel disease

Alimentary pharmacology & therapeutics, 2008-09, Vol.28 (6), p.674-688

2008

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 812

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(783)
Mit Volltextzugriff
(665)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(376)
Life Sciences & Biomedicine
(371)
Humans
(368)
Gastroenterology & Hepatology
(318)
Female
(232)
Male
(232)
Adult
(231)
Middle Aged
(192)
Biological And Medical Sciences
(176)
Medical Sciences
(176)
Aged
(118)
Gastroenterology
(117)
Gastroenterology. Liver. Pancreas. Abdomen
(109)
Crohn Disease - Drug Therapy
(105)
Stomach. Duodenum. Small Intestine. Colon. Rectum. Anus
(102)
Treatment Outcome
(101)
Inflammatory Bowel Disease
(100)
Other Diseases. Semiology
(100)
Adolescent
(94)
Crohn's Disease
(90)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Systematic review and network meta‐analysis: first‐ and second‐line biologic therapies for moderate‐severe Crohn's disease

Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing: 2013 Update

Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing

Long‐term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy

Adalimumab for the treatment of fistulas in patients with Crohn’s disease

A retrospective analysis: the development of patient reported outcome measures for the assessment of Crohn's disease activity

Development of interim patient‐reported outcome measures for the assessment of ulcerative colitis disease activity in clinical trials

The epidemiology and natural history of Crohn’s disease in population‐based patient cohorts from North America: a systematic review

PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis

Review article: dose optimisation of infliximab for acute severe ulcerative colitis

Randomised clinical trial: the safety and tolerability of Trichuris suis ova in patients with Crohn's disease

Long‐term safety and efficacy of certolizumab pegol in the treatment of Crohn's disease: 7‐year results from the PRECiSE 3 study

One‐year maintenance outcomes among patients with moderately‐to‐severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2

Randomised clinical trial: certolizumab pegol for fistulas in Crohn’s disease – subgroup results from a placebo‐controlled study

A prospective cohort study to determine the relationship between serum infliximab concentration and efficacy in patients with luminal Crohn's disease

Quantitative measurement and visual assessment of ileal Crohn’s disease activity by computed tomography enterography: correlation with endoscopic severity and C reactive protein

Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD‐subgroup analyses across four randomized trials

Review article: biological activity markers in inflammatory bowel disease

Review article: moving towards common therapeutic goals in Crohn's disease and rheumatoid arthritis

Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn's disease

Systematic review: the management of pouchitis

CDP571, a humanised monoclonal antibody to tumour necrosis factor α, for moderate to severe Crohn’s disease: a randomised, double blind, placebo controlled trial

Review article: a clinician's guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease

Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn’s disease

Review article: treatment algorithms to maximize remission and minimize corticosteroid dependence in patients with inflammatory bowel disease

Suchergebnisse filtern